Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3847065 | Advances in Chronic Kidney Disease | 2011 | 12 Pages |
Abstract
Judicious control of PO4 early in CKD, possibly monitored by measures of FGF-23, could potentially reduce the risk of development of renal secondary hyperparathyroidism and all of the adverse clinical consequences of poorly controlled CKD-mineral and bone disorder. The mainstays of therapy are likely to include a balance of dietary restriction and PO4 binders to reduce PO4 input, and in ESRD patients, dialysis modalities to augment PO4 output.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Donald A. Molony, Brett W. Stephens,